Date: September 22nd and 23rd
Format: In person
Local: Sirio-Libanês Ensino e Pesquisa | Rua Professor Daher Cutait, 69 - Bela Vista
Coordination:
• Dra. Maria Cristina Seiwald
• Dra. Yana Novis
Presentation:
The International Conference on Updates in Onco-Hematology and Cell Therapy aims to bring the latest in these areas, which have seen great scientific progress in recent years. It aims to promote the exposition and debate of themes, in addition to encouraging interaction between participants and speakers.
The event will address the latest and most relevant advances in these fields, issues that directly impact the day-to-day clinical care, presenting and discussing them with a critical view on the subject.
There will be the opportunity to witness and interact with international and national speakers, professionals who are world references in areas of hematology, such as acute leukemias, chronic lymphoproliferative diseases, lymphomas, plasma cell neoplasms, bone marrow transplantation and CAR-T cells.
We look forward to seeing you all at the event, welcome!
Target Audience:
• Physicians specializing in hematology, onco-hematology and bone marrow transplantation
Goals:
• Update in Hematology, focusing on onco-hematology
• Bone marrow transplant
• Cell therapy
Differentials:
• International Speakers
• Interactive classes
Certificates: The certificate will be released within 15 days after the event, on the registration platform.
Parking: Third-party service provided by the company INDIGO, prices from R$ 100.00 for a period of 10 hours. Consult values upon arrival.
Maria Cristina N. Seiwald, MD
Yana Novis, MD
Craig Moskowitz, MD
.svg)
Gilles Sales, MD
PhD
Gloria Iacoboni, MD
Maria Victoria Mateos, MD
PhD
Miguel Angel Perales, MD
Othman Al-Sawaf, MD
Richard M. Stone, MD
Robin Foà, MD
Fabio Kerbauy, MD
PhD
Giancarlo Fatobene, MD
Guilherme Duffles, MD
Guilherme Perini, MD
Jessica Ramos, MD
PhD
Otavio Baiocchi, MD
Phd
Vania Hungría, MD
Andre Domingues, MD
PhD
Aliana Meneses, MD
Anita Cortez, MD
Amanda Rassi, MD
Phd
Amanda Udo, MD
Ana Rita Fonseca, MD
PhD
Erick Menezes, MD
Dra. Luciana Tucunduva, MD
Mariana Serpa, MD
Martha Mariana Arruda, MD
PhD
| Schedule: Friday, 22nd of September 2023
*Programming subject to changes and guest confirmations |
|
 Participation live online |
|
 Recorded video participation |
|
| 08h00 | Registration In-Person: Ensino e Pesquisa Sírio-Libanês, São Paulo |
| 08h30 – 08h40 |
Opening Dra. Yana Novis e Dra. Maria Cristina Seiwald |
|
Session: ALL Chairs: Dra. Luciana Tucunduva e Dra. Maria Cristina Seiwald |
|
| 08h40 – 09h00 |
Current treatment of ALL – how to choose the best protocol? Dr. Robin Foà 
|
| 09h00 - 09h20 |
Ph + ALL in 2023: is there an optimal approach? Dr. Robin Foà
|
| 09h20 - 09h40 |
HCST after CAR-T cells for ALL – is it a must? Dr. Miguel Angel Perales |
| 09h40 – 10h00 |
Q & A Dr. Robin Foà e Dr. Miguel Angel Perales
|
| 10h00 – 10h30 | Break |
|
Session: Aggressive Lymphomas Chairs: Dr. Erick Xavier e Dra. Yana Novis |
|
| 10h30 – 10h50 |
Recent developments in the treatment of DLBCL, besides CAR-T cells Dr. Gilles Salles
|
| 10h50 – 11h10 |
Mantle cell lymphoma first line treatment – is BMT upfront no longer needed? Dr. Gilles Salles
|
| 11h10 – 11h30 |
CAR-T cell therapy vs Auto in RR DLBCL Dr. Miguel Angel Perales |
| 11h30 – 11h50 |
Q & A Dr. Gilles Salles e Dr. Miguel Angel Perales
|
|
Session: CAR-T Cells Chairs: Dr. Miguel Angel Perales e Dra. Ana Rita Fonseca |
|
| 11h50 – 12h10 |
Preparing for CAR T-cell therapy: patient selection, bridging therapies and lymphodepletion Dra. Gloria Iacoboni
|
| 12h10 – 12h30 | Vaccination and prophylaxis for CAR-T patients Dra. Jessica Ramos |
| 12h30 – 12h50 |
How to manage CAR -T Cell toxicities: real world experience Dra. Gloria Iacoboni
|
| 12h50 – 13h10 |
Q & A Dra. Gloria Iacoboni e Dra. Jessica Ramos
|
13h10 - 13h55  |
Satellite Symposium Kite – CAR-T Cells |
|
Session: Multiple Myeloma Chairs: Dra. Mariana Serpa e Dra. Anita Cortez |
|
| 14h00 – 14h20 |
Smoldering Myeloma – to treat or not to treat? Dra. Maria Victoria Mateos
|
| 14h20 – 14h40 |
Current approach to frontline therapy for transplant eligible patients: most recent data and role of BMT Dra. Vania Hungria |
| 14h40 – 15h00 |
Immunotherapy for multiple myeloma – biespecifics + CAR T Dra. Maria Victoria Mateos
|
| 15h00 – 15h20 |
Q & A Dra. Vania Hungria e Dra. Maria Victoria Mateos
|
15h20 - 15h50  |
Satellite Symposium Janssen – Multiple Myeloma |
| 15h50 – 16h20 | Break |
|
Session: Hodgkin Lymphoma Chairs: Dra. Yana Novis e Dr. Otavio Baiocchi |
|
| 16h20 – 17h00 |
Current state of Hodgkin Lymphoma Dr. Craig Moskowitz
|
| 17h00 –17h20 |
Question and Answer Session Dr. Craig Moskowitz
|
|
Session: Bone Marrow Transplant – BMT Chairs: Dra. Aliana Meneses e Dr. André Domingues Pereira |
|
| 17h20 – 17h40 |
Optimizing GVHD prophylaxis: Post Cy for everyone, and ATG? Dr. Miguel Angel Perales |
| 17h40 – 18h00 |
Chronic GVHD: current approach and novel drugs Dr. Giancarlo Fatobene |
| 18h00 – 18h20 |
Q & A Dr. Miguel Angel Perales e Dr. Giancarlo Fatobene |
| Schedule: Saturday, 23rd of September 2023
*Programming subject to changes and guest confirmations |
|
|
Session: AML/MDS Chairs: Dra. Maria Cristina Seiwald e Dra. Amanda Rassi |
|
| 08h40 – 09h00 |
New classification for AML/MDS and importance of NGS in current approach Dr. Richard M. Stone |
| 09h00 – 09h20 |
Novel therapies for AML Dr. Richard M. Stone |
| 09h20 – 09h40 |
Management of patients with lower-risk MDS Dr. Fabio Kerbauy |
| 09h40 – 10h00 |
Q&A Dr. Richard M. Stone e Dr. Fabio Kerbauy |
| 10h00 – 10h30 | Break |
|
Session: Indolent Lymphomas Chairs: Dra. Martha Mariana e Dra. Amanda Udo |
|
| 10h30 – 10h50 |
Follicular Lymphoma: When should autologous stem cell transplant or cellular therapy be considered? Dr. Guilherme Perini |
| 10h50 – 11h10 |
Management of Marginal Zone Lymphoma Dr. Guilherme Duffles |
| 11h10 – 11h30 |
Q&A Dr. Guilherme Perini e Dr. Guilherme Duffles |
11h30 – 12h10  |
Satellite Symposium Beigene – Novel therapies for indolent B cell Lymphomas |
|
Session: CLL Chairs: Dra. Ana Rita Fonseca e Dr. Andre Domingues |
|
| 12h10 – 12h30 |
Selecting initial therapy in CLL Dr. Othman Al Sawaf
|
| 12h30 – 12h50 |
Relapse/Refractory CLL: where are we now? Dr. Othman Al Sawaf
|
| 12h50 – 13h10 |
Q&A Dr. Othman Al Sawaf
|
| 13h10 – 13h15 | Closure |